Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 2 study titled ‘A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)’. The study aims to assess the safety and efficacy of AMG 193, a drug intended for patients with MTAP-deleted advanced NSCLC, a condition with limited treatment options.
The intervention being tested is AMG 193, an oral drug administered in film-coated tablet form. The study will evaluate two dose levels to determine the optimal dosage for further research.
The study is designed as an interventional trial with a randomized allocation and a sequential intervention model. There is no masking involved, and the primary purpose is treatment. The study consists of two parts: dose evaluation and dose expansion.
The study began on December 26, 2024, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This clinical update could positively impact Amgen’s stock performance by showcasing its commitment to innovative cancer treatments. The study’s success could enhance investor sentiment and position Amgen favorably against competitors in the oncology market.
The study is ongoing, and further details are available on the ClinicalTrials portal.